190 related articles for article (PubMed ID: 24011954)
41. Discovery of 5-(3-Chlorophenylamino)benzo[
Wang Y; Lv Z; Chen F; Wang X; Gou S
J Med Chem; 2021 Apr; 64(8):5082-5098. PubMed ID: 33834781
[TBL] [Abstract][Full Text] [Related]
42. Salicylaldehyde derivatives as new protein kinase CK2 inhibitors.
Prudent R; López-Ramos M; Moucadel V; Barette C; Grierson D; Mouawad L; Florent JC; Lafanechère L; Schmidt F; Cochet C
Biochim Biophys Acta; 2008 Dec; 1780(12):1412-20. PubMed ID: 18674590
[TBL] [Abstract][Full Text] [Related]
43. Discovery of 2,6-disubstituted pyrazine derivatives as inhibitors of CK2 and PIM kinases.
Gingipalli L; Block MH; Bao L; Cooke E; Dakin LA; Denz CR; Ferguson AD; Johannes JW; Larsen NA; Lyne PD; Pontz TW; Wang T; Wu X; Wu A; Zhang HJ; Zheng X; Dowling JE; Lamb ML
Bioorg Med Chem Lett; 2018 May; 28(8):1336-1341. PubMed ID: 29559278
[TBL] [Abstract][Full Text] [Related]
44. Synthesis, docking and in vitro anticancer evaluation of some new benzopyrone derivatives.
El-Ansary SL; Hussein MM; Abdel Rahman DE; Abdel Ghany LM
Bioorg Chem; 2014 Apr; 53():50-66. PubMed ID: 24607350
[TBL] [Abstract][Full Text] [Related]
45. A new family of densely functionalized fused-benzoquinones as potent human protein kinase CK2 inhibitors.
Martín-Acosta P; Haider S; Amesty Á; Aichele D; Jose J; Estévez-Braun A
Eur J Med Chem; 2018 Jan; 144():410-423. PubMed ID: 29288942
[TBL] [Abstract][Full Text] [Related]
46. Structure-based design and synthesis of novel macrocyclic pyrazolo[1,5-a] [1,3,5]triazine compounds as potent inhibitors of protein kinase CK2 and their anticancer activities.
Nie Z; Perretta C; Erickson P; Margosiak S; Lu J; Averill A; Almassy R; Chu S
Bioorg Med Chem Lett; 2008 Jan; 18(2):619-23. PubMed ID: 18055206
[TBL] [Abstract][Full Text] [Related]
47. Structural features underlying the selectivity of the kinase inhibitors NBC and dNBC: role of a nitro group that discriminates between CK2 and DYRK1A.
Sarno S; Mazzorana M; Traynor R; Ruzzene M; Cozza G; Pagano MA; Meggio F; Zagotto G; Battistutta R; Pinna LA
Cell Mol Life Sci; 2012 Feb; 69(3):449-60. PubMed ID: 21720886
[TBL] [Abstract][Full Text] [Related]
48. Inspecting the structure-activity relationship of protein kinase CK2 inhibitors derived from tetrabromo-benzimidazole.
Battistutta R; Mazzorana M; Sarno S; Kazimierczuk Z; Zanotti G; Pinna LA
Chem Biol; 2005 Nov; 12(11):1211-9. PubMed ID: 16298300
[TBL] [Abstract][Full Text] [Related]
49. Quinone reductase 2 is an adventitious target of protein kinase CK2 inhibitors TBBz (TBI) and DMAT.
Leung KK; Shilton BH
Biochemistry; 2015 Jan; 54(1):47-59. PubMed ID: 25379648
[TBL] [Abstract][Full Text] [Related]
50. Structural determinants of CX-4945 derivatives as protein kinase CK2 inhibitors: a computational study.
Liu H; Wang X; Wang J; Wang J; Li Y; Yang L; Li G
Int J Mol Sci; 2011; 12(10):7004-21. PubMed ID: 22072932
[TBL] [Abstract][Full Text] [Related]
51. Structure-based design of novel potent protein kinase CK2 (CK2) inhibitors with phenyl-azole scaffolds.
Hou Z; Nakanishi I; Kinoshita T; Takei Y; Yasue M; Misu R; Suzuki Y; Nakamura S; Kure T; Ohno H; Murata K; Kitaura K; Hirasawa A; Tsujimoto G; Oishi S; Fujii N
J Med Chem; 2012 Mar; 55(6):2899-903. PubMed ID: 22339433
[TBL] [Abstract][Full Text] [Related]
52. Development of a potent and selective chemical probe for the pleiotropic kinase CK2.
Wells CI; Drewry DH; Pickett JE; Tjaden A; Krämer A; Müller S; Gyenis L; Menyhart D; Litchfield DW; Knapp S; Axtman AD
Cell Chem Biol; 2021 Apr; 28(4):546-558.e10. PubMed ID: 33484635
[TBL] [Abstract][Full Text] [Related]
53. A subnanomolar fluorescent probe for protein kinase CK2 interaction studies.
Enkvist E; Viht K; Bischoff N; Vahter J; Saaver S; Raidaru G; Issinger OG; Niefind K; Uri A
Org Biomol Chem; 2012 Nov; 10(43):8645-53. PubMed ID: 23032938
[TBL] [Abstract][Full Text] [Related]
54. Evaluation of 3-carboxy-4(1H)-quinolones as inhibitors of human protein kinase CK2.
Golub AG; Yakovenko OY; Bdzhola VG; Sapelkin VM; Zien P; Yarmoluk SM
J Med Chem; 2006 Nov; 49(22):6443-50. PubMed ID: 17064064
[TBL] [Abstract][Full Text] [Related]
55. Synthesis and biological evaluation of 2,6-di(furan-3-yl)anthracene-9, 10-dione as an inhibitor of human protein kinase CK2.
Haidar S; Meyers A; Bollacke A; Jose J
Pharmazie; 2015 Dec; 70(12):772-6. PubMed ID: 26817273
[TBL] [Abstract][Full Text] [Related]
56. Synthesis of novel polybrominated benzimidazole derivatives-potential CK2 inhibitors with anticancer and proapoptotic activity.
Łukowska-Chojnacka E; Wińska P; Wielechowska M; Poprzeczko M; Bretner M
Bioorg Med Chem; 2016 Feb; 24(4):735-41. PubMed ID: 26778657
[TBL] [Abstract][Full Text] [Related]
57. The CK2 alpha/CK2 beta interface of human protein kinase CK2 harbors a binding pocket for small molecules.
Raaf J; Brunstein E; Issinger OG; Niefind K
Chem Biol; 2008 Feb; 15(2):111-7. PubMed ID: 18291315
[TBL] [Abstract][Full Text] [Related]
58. Exploring the Pivotal Role of the CK2 Hinge Region Sub-Pocket in Binding with Tricyclic Quinolone Analogues by Computational Analysis.
Zhou Y; Zhang N; Tang S; Qi X; Zhao L; Zhong R; Peng Y
Molecules; 2017 May; 22(5):. PubMed ID: 28534839
[TBL] [Abstract][Full Text] [Related]
59. An unbiased evaluation of CK2 inhibitors by chemoproteomics: characterization of inhibitor effects on CK2 and identification of novel inhibitor targets.
Duncan JS; Gyenis L; Lenehan J; Bretner M; Graves LM; Haystead TA; Litchfield DW
Mol Cell Proteomics; 2008 Jun; 7(6):1077-88. PubMed ID: 18258654
[TBL] [Abstract][Full Text] [Related]
60. Synthesis of novel chiral TBBt derivatives with hydroxyl moiety. Studies on inhibition of human protein kinase CK2α and cytotoxicity properties.
Borowiecki P; Wawro AM; Wińska P; Wielechowska M; Bretner M
Eur J Med Chem; 2014 Sep; 84():364-74. PubMed ID: 25036794
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]